Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma.

ESMO Gastrointest Oncol · 2025 · PMC12836607 · PMID 41646274

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In this study, patients with a PD-L1 TPS ≥1% showed a trend toward improved PFS compared with those with a TPS <1% in the ICI + chemo group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.